Cell-free Fetal DNA Concentration in Cases of Abnormal Placental Invasion .

Predictive Value of Cell-free Fetal DNA Concentration in the Maternal Plasma for Abnormal Placental Invasion in Cases of Placenta Previa.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03638024

Enrollment

Registered

2018-08-20

Start date

2018-09-01

Completion date

2019-04-03

Last updated

2018-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Placenta Accreta, Placenta Increta, Placenta Percreta, Placenta Previa

Brief summary

Cell free fetal DNA might predict abnormal placental invasion

Detailed description

This study aims to evaluate whether measurement of cell-free fetal DNA in the maternal plasma can be predictive of abnormal invasion in cases of placenta previa.

Interventions

DIAGNOSTIC_TESTMaternal plasma cell free fetal DNA levels

Measurement Maternal plasma cell free fetal DNA levels in both groups (study and control groups)

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Inclusion criteria

1. Maternal age range from 20-40 years old. 2. Parity: para 1- para 5. 3. Body mass index range from 18-25 kg/m2. 4. Singleton pregnancy carrying male fetuses. 5. Gestational age range from 28-34 weeks.

Exclusion criteria

1. Multifetal pregnancy. 2. Hypertension, preterm labor and intrauterine growth restriction. 3. Patients taking a tocolytic agent or those with uterine bleeding at or after blood sampling. * Since these complications may increase the level of cell-free fetal DNA. 4. Accidental hemorrhage.

Design outcomes

Primary

Measure	Time frame	Description
Predictive value of maternal plasma cell free DNA	4 months	Prediction of abnormal placental invasion in cases of placenta previa. Primary aim: Is to evaluate whether measurement of cell-free fetal DNA in the maternal plasma can be predictive of abnormal placental invasion in cases of placenta previa. Secondary aim: To decrease maternal morbidity and mortality by early prenatal diagnosis of abnormal placental invasion in placenta previa

Secondary

Measure	Time frame	Description
maternal morbidity	4 months	maternal morbidity

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026